\u25cf ArisGlobal announces acquisition of Boehringer Ingelheim\u2019s Benefit-Risk Analytic System (BRASS), a software solution designed to support causal analysis of drug safety data in a highly regulated environment<\/p>\n
\u25cf As a part of the LifeSphere\u00ae platform, this solution will be named LifeSphere Clarity and will unlock crucial data patterns leveraging machine learning<\/p>\n
\u25cf Rapid, robust benefit-risk assessment is key for all organizations collecting and processing large safety data sets<\/p>\n
\u25cf Intelligent tool will drive industry-wide advancement of pharmacovigilance and patient safety capabilities<\/p>\n
Miami, U.S.; Ingelheim, Germany \u2013 [May 11, 2022] \u2013 ArisGlobal, the global market leader in drug safety solutions worldwide, and Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced the acquisition of Boehringer Ingelheim\u2019s digital innovation, BRASS, by ArisGlobal. This data insights engine will be integrated into ArisGlobal\u2019s technology platform, LifeSphere\u00ae, under the name of LifeSphere Clarity, and will play a key role in driving industry-wide advancement of pharmacovigilance and patient safety.<\/p>\n
LifeSphere Clarity is an intelligent signal analytics technology that provides insights which are otherwise challenging or impossible to find. Jointly developed by Boehringer Ingelheim\u2019s Patient Safety and Technology teams, the digital engine leverages automation and artificial intelligence to consolidate patient safety data, reveals possible reasons why things happened, and allows modeling the possible impact of different influences.<\/p>\n
Once integrated into the LifeSphere platform, users will be presented with valuable connections and gain deeper insights, faster. Making this tool available within the LifeSphere platform will harness the user community\u2019s input to make better automated suggestions on possible causal patterns influencing adverse events. Ultimately, this will give the safety specialist user within a pharmaceutical company the ability to create a more efficient medical benefit-risk analysis. This informative technology will advance ArisGlobal\u2019s LifeSphere Data and Analytics initiative, delivering complementary capabilities to LifeSphere Signal and Risk Management as one example of the application for the technology.<\/p>\n
\u201cAt Boehringer Ingelheim, we always put the patients first. BRASS (soon to become LifeSphere Clarity) is a system that can help a pharmaceutical company understand the whole network of how diseases, comorbidities, effects, and side effects of medications, as well as medical events influence each other. The ambition is to ensure that each patient gets the best and safest therapy option for them, and robust and rapid benefit-risk assessment also helps get the right therapies to patients faster.\u201d states Robert Buchberger, Head of Patient Safety & Pharmacovigilance at Boehringer Ingelheim. \u201cWe are very pleased to be building on our partnership with ArisGlobal to make this innovative technology accessible to other pharma companies for the benefit of patients,\u201d adds Markus Sch\u00fcmmelfeder, Head of IT at Boehringer Ingelheim.<\/p>\n
\u201cWith our deep industry expertise, ArisGlobal is uniquely positioned to synthesize these powerful insights for our life sciences customers,\u201d shares Pat Jenakanandhini, Chief Product Officer at ArisGlobal. \u201cIt\u2019s also a marquee moment in the industry as this technology did not come from a software startup but in fact was built and validated by one of the world\u2019s leading pharmaceutical companies \u2014providing a unique and valuable capability that will resonate with other customers, including but not limited to those already using or exploring LifeSphere Signal and Risk Management as a signal and risk tool.\u201d<\/p>\n
This digital innovation represents impactful progress industry-wide, as it opens an opportunity for many life sciences organizations to advance their pharmacovigilance analytics and insights. It is also representative of the power of partnership across the life sciences industry, as Boehringer Ingelheim and ArisGlobal have worked collaboratively for over three decades, continually striving for, and achieving, pharmacovigilance innovation.<\/p>\n","protected":false},"excerpt":{"rendered":"
\u25cf ArisGlobal announces acquisition of Boehringer Ingelheim\u2019s Benefit-Risk Analytic System […]<\/p>\n","protected":false},"author":27,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[65],"tags":[],"class_list":["post-46812","post","type-post","status-publish","format-standard","hentry","category-press-release"],"acf":[],"yoast_head":"\n